- Home
- ARVN vs URGN Comparison
ARVN vs URGN Comparison
Compare ARVN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- URGN
- Stock Information
- Founded
- ARVN 2015
- URGN 2004
- Country
- ARVN United States
- URGN United States
- Employees
- ARVN N/A
- URGN N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- URGN Health Care
- Exchange
- ARVN Nasdaq
- URGN Nasdaq
- Market Cap
- ARVN 438.1M
- URGN 465.9M
- IPO Year
- ARVN 2018
- URGN 2017
- Fundamental
- Price
- ARVN $9.12
- URGN $10.18
- Analyst Decision
- ARVN Buy
- URGN Strong Buy
- Analyst Count
- ARVN 15
- URGN 7
- Target Price
- ARVN $31.86
- URGN $37.21
- AVG Volume (30 Days)
- ARVN 2.8M
- URGN 487.2K
- Earning Date
- ARVN 05-06-2025
- URGN 05-12-2025
- Dividend Yield
- ARVN N/A
- URGN N/A
- EPS Growth
- ARVN N/A
- URGN N/A
- EPS
- ARVN N/A
- URGN N/A
- Revenue
- ARVN $263,399,999.00
- URGN $90,398,000.00
- Revenue This Year
- ARVN N/A
- URGN $38.65
- Revenue Next Year
- ARVN N/A
- URGN $118.69
- P/E Ratio
- ARVN N/A
- URGN N/A
- Revenue Growth
- ARVN 235.54
- URGN 9.29
- 52 Week Low
- ARVN $5.94
- URGN $8.94
- 52 Week High
- ARVN $37.38
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- ARVN 52.04
- URGN 45.94
- Support Level
- ARVN $5.94
- URGN $9.36
- Resistance Level
- ARVN $6.86
- URGN $10.83
- Average True Range (ATR)
- ARVN 0.55
- URGN 0.78
- MACD
- ARVN 0.58
- URGN -0.06
- Stochastic Oscillator
- ARVN 93.47
- URGN 45.12
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.